Testing MTX-474 for diffuse scleroderma
Part of Skin clinical trials.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse scleroderma (systemic sclerosis) that affects your skin and other parts of your body.
- Your skin thickening is still active – either within 2 years of your first symptom (other than Raynaud's), or up to 10 years if your skin score is in a certain range and you haven't had spontaneous improvement.
- You are at least 18 years old and able to give written consent.
- Your lung function tests show a forced vital capacity (FVC) of 45% or more and a diffusion capacity (DLCO) of 30% or more.
- You are not currently on certain medications like high-dose steroids, strong immunosuppressants, or other experimental drugs, or you can safely stop them before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests a treatment called extracorporeal photopheresis (ECP) for people with early diffuse systemic sclerosis (scleroderma). ECP is a procedure where your blood is treated with light and a medication, then returned to your body, and it may help reduce skin thickening and other symptoms.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.